CorMedix Inc.
CRMD · XNASCIK 1410098fmd_17PBVDYE08HENJ6HCB31EPGNHRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 70 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 43 | 312 |
| Rental revenue | – | – | – | 0 | – | – | – | – | – | – |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 3 | 22 |
| Net interest income | – | – | – | – | – | – | – | – | 1 | – |
| Gross profit | (0) | 0 | 0 | (0) | 0 | 0 | 0 | – | 40 | 276 |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Research and development | 16 | 24 | 19 | 11 | 13 | 13 | 11 | 13 | 4 | 19 |
| Selling, general and administrative | – | – | 8 | 10 | 14 | 16 | 20 | 36 | 59 | 106 |
| Total operating expenses | 25 | 33 | 27 | 21 | 27 | 29 | 31 | 49 | 63 | 126 |
| Operating income | (25) | (33) | (27) | (21) | (27) | (29) | (31) | (49) | (22) | 150 |
| Interest expense | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | – | 3 | 3 | 4 |
| Other non-operating income (expense) | – | (0) | 0 | (0) | 0 | (0) | 0 | 3 | 3 | (0) |
| Income before taxes | (25) | (33) | (27) | (21) | (27) | (29) | (30) | (46) | (19) | 150 |
| Income tax expense | – | – | – | (5) | (5) | (1) | (1) | – | (1) | (13) |
| Net income from continuing operations | – | – | – | (16) | (22) | (28) | (30) | (46) | (18) | 2 |
| Net income | (25) | (33) | (27) | (16) | (22) | (28) | (30) | (46) | (18) | 163 |
| Net income to common shareholders | (25) | – | (27) | (44) | (22) | – | – | – | – | – |